Author information
1 Assistant Professor of Population Health, Dell Medical School - The University of Texas at Austin, Assistant Professor of Medicine, Department of Medicine, Johns Hopkins School of Medicine (Leung), Osteopathic Medicine Student-II, University of the Incarnate Word School of Osteopathic Medicine (Bernacki), Professor of Population Health, Dell Medical School-The University of Texas at Austin, Professor Emeritus of Medicine, Department of Medicine, Johns Hopkins University School of Medicine (Bernacki).
Abstract
OBJECTIVE:
To evaluate medical and pharmaceutical costs and health outcomes among commercially-insured members treated for Hepatitis C (HCV) infections from a large, academic institution.
METHODS:
Data is derived from the University of Texas System (UT SELECT) medical and pharmacy claims database. This study is a retrospective claims analysis of secondary, de-identified data from 2006-2016.
RESULTS:
The number of HCV infected and treated patients decreased from 22.5 per 10,000 members in 2006 to 0.15 per 10,000 members in 2016 (p?
CONCLUSIONS:
The declining prevalence of acute HCV infections and the introduction of efficacious HCV treatment options for chronic HCV in this commercial population have resulted in significant reductions in HCV-related medical claims and the clinical sequelae of advanced liver diseases. While HCV treatment to achieve sustained viral response (SVR) remains expensive, the prevention of advanced liver disease decreased system-wide medical costs for this insured population.